TCGA-22-4601-01A-01R-1443-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.290
- KRAS_SIGNALING_DN+0.190
- SPERMATOGENESIS+0.150
- E2F_TARGETS+0.130
- P53_PATHWAY+0.130
- MITOTIC_SPINDLE+0.110
- G2M_CHECKPOINT+0.090
- HEDGEHOG_SIGNALING+0.090
- PI3K_AKT_MTOR_SIGNALING+0.070
- MYC_TARGETS_V1+0.040
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- IL6_JAK_STAT3_SIGNALING-0.410
- ANGIOGENESIS-0.390
- COMPLEMENT-0.320
- KRAS_SIGNALING_UP-0.320
- INFLAMMATORY_RESPONSE-0.310
- INTERFERON_GAMMA_RESPONSE-0.310
- ANDROGEN_RESPONSE-0.290
- COAGULATION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-A4BX-01A-11R-A24H-07 | — | cohortSQ2 | 0.854 |
| 2 | SRR12202412 | — | — | 0.850 |
| 3 | TCGA-56-7730-01A-11R-2125-07 | — | cohortSQ2 | 0.849 |
| 4 | TCGA-NC-A5HT-01A-11R-A26W-07 | — | cohortSQ1 | 0.826 |
| 5 | TCGA-J1-A4AH-01A-31R-A24H-07 | — | cohortSQ2 | 0.824 |
| 6 | SRR1318407 | GTEX | — | 0.818 |
| 7 | SRR604146 | GTEX | — | 0.818 |
| 8 | SRR1401062 | GTEX | — | 0.806 |
| 9 | SRR1337119 | GTEX | — | 0.805 |
| 10 | SRR817258 | GTEX | — | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.130 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.090 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.040 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.010 | Idelalisib | — uncovered |